Next Issue
Volume 6, December
Previous Issue
Volume 6, August
 
 
siuj-logo

Journal Browser

Journal Browser

Soc. Int. Urol. J., Volume 6, Issue 5 (October 2025) – 9 articles

Cover Story (view full-size image): Société Internationale d’Urologie Journal (SIUJ) is an international, peer-reviewed, open access journal that covers all aspects of urology and related fields. SIUJ is the official journal of the Société Internationale d’Urologie (SIU) and is published bimonthly online by MDPI (since Volume 5, Issue 1 - 2024).
  • Issues are regarded as officially published after their release is announced to the table of contents alert mailing list.
  • You may sign up for e-mail alerts to receive table of contents of newly released issues.
  • PDF is the official format for papers published in both, html and pdf forms. To view the papers in pdf format, click on the "PDF Full-text" link, and use the free Adobe Reader to open them.
Order results
Result details
Select all
Export citation of selected articles as:
581 pages, 5425 KB  
Conference Report
Abstracts of the 45th Congress of the Société Internationale d’Urologie
by Société Internationale d’Urologie
Soc. Int. Urol. J. 2025, 6(5), 67; https://doi.org/10.3390/siuj6050067 - 21 Oct 2025
Viewed by 44
Abstract
The SIU wishes to extend its gratitude to the urologists who contributed their time to review abstract submissions for the 45th SIU Congress.[...] Full article
11 pages, 858 KB  
Article
Long-Term Patient-Reported Outcomes of Hyperbaric Oxygen Therapy for Haematuria Due to Radiation Cystitis Secondary to External Beam Radiotherapy for Pelvic Malignancy
by Thomas Milton, Darcy Noll, Peter Stapleton, Henry Shaw, Joseph Hewitt, Marcus Kha, Troy Pudney, Hien Le, Adrian Winsor and Rajinder Singh-Rai
Soc. Int. Urol. J. 2025, 6(5), 66; https://doi.org/10.3390/siuj6050066 - 21 Oct 2025
Viewed by 95
Abstract
Background/Objectives: To determine long-term patient-reported outcomes for patients undergoing hyperbaric oxygen therapy (HBO2) following external beam radiotherapy. Methods: A retrospective cohort study of all consecutive patients who underwent HBO2 for radiation cystitis in South Australia from September 2017 to March 2023 [...] Read more.
Background/Objectives: To determine long-term patient-reported outcomes for patients undergoing hyperbaric oxygen therapy (HBO2) following external beam radiotherapy. Methods: A retrospective cohort study of all consecutive patients who underwent HBO2 for radiation cystitis in South Australia from September 2017 to March 2023 was performed. Patient-reported symptom severity, anxiety, healthcare use and transfusion requirements pre- and post-treatment were collected through telephone interview. Readmission data and procedural data was collected through both telephone interview and a state-wide electronic medical record. Jamovi was used to perform paired sample t-tests for statistical analysis. Results: There were 89 patients who underwent HBO2 for radiation cystitis with 54 completing the questionnaire. There were 85% of patients alive at the time of follow-up, with 61% of the total cohort and 74% of survivors completing the questionnaire. For those completing the questionnaire, 96% were male with all of them having prostate cancer. Median age was 74 (interquartile range [IQR] 69–78). The mean reduction in patients’ perceived symptom severity after HBO2 on a scale out of 10 was 7.9 to 2 with a difference of 5.9 (95% confidence interval [CI] 5.1–6.7, p < 0.001) and the mean reduction in perceived anxiety was 6.9 to 2.1 with a difference of 4.7 (95% CI 3.6–5.8 p < 0.001). Patients reported a reduction in family doctor visits from 2.7 to 0.76 with a mean reduction of 2 (95% CI 0.8 to 3.2, p = 0.003), emergency department presentations from 3.3 to 0.57 with a mean reduction of 2.7 (95% CI 1.4–4.1, p ≤ 0.001) and blood transfusions from 0.67 to 0.31 with a mean reduction of 0.34 (95% CI −0.44 to 1.1, p = 0.017). Ongoing haematuria was reported in 21 of the 54 patients (39%). Further treatment was required for 20 patients (25%). No patients reported any severe or ongoing adverse effects from HBO2 via the questionnaire. Conclusions: HBO2 is a safe option for recurrent haematuria due to radiation cystitis with high patient satisfaction and reduction in patient-perceived symptom severity, anxiety and healthcare utilisation. Level of evidence: 4. Full article
Show Figures

Figure 1

15 pages, 1017 KB  
Systematic Review
Spontaneous Stone Passage Rates of Ureteric Stones After Stenting for Acute Renal Colic: A Systematic Review
by Sean Lim, Patrick Gordon, Daryl Thompson, Damien Bolton, Oneel Patel and Joseph Ischia
Soc. Int. Urol. J. 2025, 6(5), 65; https://doi.org/10.3390/siuj6050065 - 21 Oct 2025
Viewed by 90
Abstract
Background/Objectives: Renal colic poses a significant burden on patients and healthcare systems. Negative ureteroscopy in the setting of stented patients is reported at up to 14%, resulting in unnecessary surgeries and inefficiencies. While ureteral stents have demonstrated efficacy in relieving obstruction, their exact [...] Read more.
Background/Objectives: Renal colic poses a significant burden on patients and healthcare systems. Negative ureteroscopy in the setting of stented patients is reported at up to 14%, resulting in unnecessary surgeries and inefficiencies. While ureteral stents have demonstrated efficacy in relieving obstruction, their exact effect on spontaneous stone passage (SSP) is unclear. Hence, a systematic evaluation of the literature was performed to identify the impact of ureteral stents on spontaneous stone passage rates. Methods: A systematic search was conducted in MEDLINE, Embase, and PubMed (January 1989–February 2025) to identify studies investigating indwelling ureteric stents and SSP. Two independent reviewers screened the abstracts and full texts, with a third resolving conflicts. Quality assessment was conducted using The Risk Of Bias In Non-randomized Studies—of Interventions (ROBINS-I) and Cochrane Risk of Bias 2 (RoB-2) tools. Results: A total of 2437 patients in 14 studies investigating SSP in stented patients were included. One included study was a randomised controlled trial, but the rest were observational (n = 13). Three studies compared stented and control groups, whereas 11 studies only investigated patients with stents. Mean/median overall stone sizes ranged from 4.7 to 7.8 mm in diameter. Overall, SSP rates with stents varied significantly, ranging from 1.7 to 42.3%, in the setting of variable stone size, location, duration of follow-up, and method of stone passage detection. When comparing stented and non-stented patients, two studies demonstrated impaired SSP rates in stented patients (13.9% vs. 26.8% and 14% vs. 20%), but only one of these differences was statistically significant. Three studies comparing patients with retrograde ureteral stents and nephrostomies found increased SSP rates in nephrostomy cohorts (p < 0.001). Conclusions: Stone passage rates with stents vary widely due to heterogeneity in study design, patient characteristics, and follow-up. Some studies suggest that stents may impair passage; however, evidence remains inconclusive due to the limited availability of high-quality comparative data. This study underscores the need for larger prospective trials to clarify the actual impact of stenting on stone passage. Full article
Show Figures

Graphical abstract

5 pages, 3779 KB  
Interesting Images
Nutcracker Syndrome as an Uncommon Cause of Isolated Hematuria in Adults
by Oleksandr Boiko, Soledad Larburu and David Lecumberri
Soc. Int. Urol. J. 2025, 6(5), 64; https://doi.org/10.3390/siuj6050064 - 21 Oct 2025
Viewed by 98
Abstract
Compression of the left renal vein between the abdominal aorta and superior mesenteric artery, known as nutcracker syndrome, can present with subtle, nonspecific symptoms that often delay diagnosis, posing a clinical challenge in daily urology practice and necessitating targeted imaging for accurate identification. [...] Read more.
Compression of the left renal vein between the abdominal aorta and superior mesenteric artery, known as nutcracker syndrome, can present with subtle, nonspecific symptoms that often delay diagnosis, posing a clinical challenge in daily urology practice and necessitating targeted imaging for accurate identification. We report the case of a 39-year-old patient who presented with isolated hematuria and long-standing pelvic pain and was ultimately diagnosed with nutcracker syndrome. Following the failure of endovascular therapy, the patient underwent renal autotransplantation, resulting in complete resolution of symptoms at follow-up. Full article
Show Figures

Figure 1

7 pages, 886 KB  
Article
Effectiveness of Transurethral Bulkamid Injections as an Adjunct to the AdVance XP Sling for Male Patients with Post-Prostatectomy Incontinence
by Sophie Plagakis, Joshua Makary, Thomas King, Vincent Tse and Lewis Chan
Soc. Int. Urol. J. 2025, 6(5), 63; https://doi.org/10.3390/siuj6050063 - 21 Oct 2025
Viewed by 96
Abstract
Background/Objectives: Bulkamid® (Axonics, Irvine, CA, USA) is a non-particulate polyacrylamide hydrogel used in the treatment of urinary incontinence. While its effectiveness is well-documented in female stress urinary incontinence (SUI), there is limited data on its role in male stress urinary incontinence, particularly [...] Read more.
Background/Objectives: Bulkamid® (Axonics, Irvine, CA, USA) is a non-particulate polyacrylamide hydrogel used in the treatment of urinary incontinence. While its effectiveness is well-documented in female stress urinary incontinence (SUI), there is limited data on its role in male stress urinary incontinence, particularly post-prostatectomy incontinence (PPI). This study evaluates the efficacy of Bulkamid as a primary or adjunctive treatment for male PPI. Methods: A retrospective chart review was conducted on male patients who developed PPI and underwent Bulkamid injections between 2016 and 2021. Data collected included pre- and post-procedure pad usage, the volume of Bulkamid injected, prior and subsequent incontinence treatments, and patient-reported satisfaction. Bulkamid was injected transurethrally in four quadrants near the vesicourethral anastomosis using a rigid cystoscope. Results: Twenty-one men with a history of radical prostatectomy (six open and fifteen robotic), including four who received adjuvant radiotherapy, were included. Fifteen underwent Bulkamid injection as a primary treatment, with five (33%) requiring repeat injections due to initial improvement. Eight (54%) subsequently underwent an AdVance XP® sling placement, while two (13%) required no further treatment. Six patients received Bulkamid as an adjunct to prior incontinence surgery, with 80% of post-sling patients reporting improved continence. Bulkamid was less effective in men with detrusor overactivity or prior radiation. Conclusions: Bulkamid demonstrated a higher success rate as an adjunct to the AdVance XP sling, with 80% of men experiencing improved continence. As a primary treatment for PPI, success was modest, with only 33% achieving improvement, often requiring repeat injections or conversion to a sling. Bulkamid presents a low-risk option for select male PPI patients, particularly those with prior sling placement, but durability and long-term effectiveness remain concerns. Full article
Show Figures

Figure 1

14 pages, 2702 KB  
Article
Renal Decompression for Malignant Ureteric Obstruction: A Tertiary Hospital Cohort Analysis
by Alex Buckby, Rowan David and Arman Kahokehr
Soc. Int. Urol. J. 2025, 6(5), 62; https://doi.org/10.3390/siuj6050062 - 21 Oct 2025
Viewed by 131
Abstract
Background/Objectives: Malignant ureteric obstruction is an increasingly common problem; however, its treatment remains challenging due to associated poor survival and quality of life outcomes. There is a lack of consensus on how to best manage these patients. We provide a description of [...] Read more.
Background/Objectives: Malignant ureteric obstruction is an increasingly common problem; however, its treatment remains challenging due to associated poor survival and quality of life outcomes. There is a lack of consensus on how to best manage these patients. We provide a description of the survival outcomes, renal function outcomes, complications, and prognostic factors associated with the treatment of malignant ureteric obstruction in a cohort of patients at our tertiary Urology unit. Methods: A retrospective review of prospectively identified patients treated for malignant ureteric obstruction at our tertiary Urology unit was performed. Obstruction was relieved with either retrograde insertion of a ureteric stent or percutaneous nephrostomy between the 1st of January 2018, and 31st of December 2023. Renal function, complications, and survival data were recorded. Subgroup analysis and survival analysis were performed to determine prognostic factors. Results: Eighty-four patients underwent treatment for malignant ureteric obstruction with a median survival of 197 days (3–1549 days). A total of 51% percent of patients had a stent-related complication requiring hospitalisation, resulting in a total of 966 additional days in hospital. A total of 78% of patients had improved renal function at 12 months. Factors associated with worse survival included emergency treatment of malignant ureteric obstruction, having no further oncological treatment, receiving no oncological-specific treatment for malignancy, bilateral obstruction, female gender, and poor Primary site, Laterality, serum Creatinine level, and Treatment for primary site (PLaCT) prognosis group (p =< 0.01). Conclusions: Patients with malignant ureteric obstruction have a poor prognosis despite intervention. Treatment is often futile and associated with a significant burden of complications related to ureteric stents and percutaneous nephrostomies. Full article
Show Figures

Figure 1

3 pages, 905 KB  
Interesting Images
When Bladder Cancer Treatment Strikes Back: Mycotic Aneurysms After Intravesical BCG Therapy
by Sarah Blackwell, Kevin Yinkit Zhuo, Andrew Jensen and Balasubramanian Indrajit
Soc. Int. Urol. J. 2025, 6(5), 61; https://doi.org/10.3390/siuj6050061 - 20 Oct 2025
Viewed by 100
Abstract
Intravesical Bacillus Calmette-Guerin (BCG) remains the gold standard adjuvant therapy for intermediate and high-risk non-muscle invasive bladder cancer (NMIBC) [...] Full article
Show Figures

Figure 1

15 pages, 1323 KB  
Article
The Impact of Patient Navigators on Overactive Bladder Care: Real-World Practice Patterns from a US National Database
by Ekene Enemchukwu, Jennifer Miles-Thomas, Nitya Abraham, Diane K. Newman, Marc Schwartz, Kimberly Becker Ifantides, Mariana Nelson and Raveen Syan
Soc. Int. Urol. J. 2025, 6(5), 60; https://doi.org/10.3390/siuj6050060 - 20 Oct 2025
Viewed by 98
Abstract
Background/Objectives: We here describe the impact of navigated care on utilization patterns of pharmacologic and minimally invasive overactive bladder therapies. Methods: This retrospective observational cohort study used electronic medical record data from the Precision Point Specialty Analytics Portal in the United States. Eligible [...] Read more.
Background/Objectives: We here describe the impact of navigated care on utilization patterns of pharmacologic and minimally invasive overactive bladder therapies. Methods: This retrospective observational cohort study used electronic medical record data from the Precision Point Specialty Analytics Portal in the United States. Eligible patients were adults (≥18 years) newly diagnosed and treated for non-neurogenic overactive bladder (1 January 2015 to 31 December 2019). Categorical endpoints were analyzed by chi-square test or Fisher exact test. Of 170,000 eligible patients, 8982 (≈5%) were randomly selected and stratified by navigation status (navigated: 1150 [12.8%]; non-navigated: 7832 [87.2%]). Results: Overall, 60.0% of patients were female, 69.9% were White, and 42.7% had Medicare coverage. Navigated care was more common among women, Black patients, and those covered by Medicaid/Medicare. Initial pharmacologic treatment rates were similar between navigated and non-navigated groups (anticholinergic: 57.0% vs. 57.4%; beta-3 agonist: 43.0% vs. 42.6%). Greater percentages of navigated versus non-navigated patients received minimally invasive therapy (23.8% vs. 10.8%, respectively; p < 0.0001). Discontinuation rates were lower for navigated versus non-navigated patients undergoing pharmacologic treatment (62.5% vs. 71.3%; p < 0.0001). Conclusions: Patient navigation for overactive bladder may help increase access to minimally invasive therapies and may be a tool to address treatment disparities. Full article
Show Figures

Graphical abstract

9 pages, 1094 KB  
Article
The Clinical Integration of ChatGPT Through an Augmented Patient Encounter in a Real-World Urological Cohort: A Feasibility Study
by Shane Qin, Emre Alpay, Bodie Chislett, Joseph Ischia, Luke Gibson, Damien Bolton and Dixon T. S. Woon
Soc. Int. Urol. J. 2025, 6(5), 59; https://doi.org/10.3390/siuj6050059 - 20 Oct 2025
Viewed by 100
Abstract
Background/Objectives: To evaluate the viability of using ChatGPT in a real clinical environment for patient education during informed consent for flexible cystoscopy, assessing its practicality, patient perceptions, and clinician evaluations within a urological cohort. Methods: A prospective feasibility study was conducted at a [...] Read more.
Background/Objectives: To evaluate the viability of using ChatGPT in a real clinical environment for patient education during informed consent for flexible cystoscopy, assessing its practicality, patient perceptions, and clinician evaluations within a urological cohort. Methods: A prospective feasibility study was conducted at a single institution involving patients with haematuria who attended an in-person clinic review with access to ChatGPT-4o mini. Using predetermined prompts regarding haematuria, we evaluated the accuracy, consistency, and suitability of the ChatGPT information. Responses were appraised for errors, omission of key information, and suitability for patient education. The functionality, usability, and quality of ChatGPT for patient education were assessed by three urologists using the Patient Education Materials Assessment Tool (PEMAT) and DISCERN tools. Readability was assessed using the Flesch–Kincaid tests. Further clinician questionnaires evaluated ChatGPT’s accuracy, reproducibility, and integration potential. Results: Ten patients were recruited, but one patient was excluded because he refused to use ChatGPT due to language barriers. All patients found ChatGPT to be useful, but most believed it could not entirely replace the doctor, especially for obtaining informed consent. There were no significant errors. The mean PEMAT score for understandability was 77.8%, and actionability was 63.8%. The mean DISCERN score was 57.7, corresponding to a ‘good’ quality score. The Flesch Reading Ease score was 30.2, with the writing level comparable to US grade level 13. Conclusions: ChatGPT offers valuable support for patient education, delivering accurate and comprehensive information. However, challenges with readability, contextual understanding, and actionability highlight the need for development and careful integration. Generative artificial intelligence (AI) should augment, not replace, clinician–patient interactions, emphasising ethical considerations and patient trust. This study provides a basis for further exploration of AI’s role in healthcare. Full article
Show Figures

Figure 1

Previous Issue
Next Issue
Back to TopTop